Li S - Search Results

1

Optimal co-clinical radiomics: Sensitivity of radiomic features to tumour volume, image noise and resolution in co-clinical T1-weighted and T2-weighted magnetic resonance imaging.

Roy S, Whitehead TD, Quirk JD, Salter A, Ademuyiwa FO, Li S, An H, Shoghi KI. Roy S, et al. Among authors: li s. EBioMedicine. 2020 Sep;59:102963. doi: 10.1016/j.ebiom.2020.102963. Epub 2020 Sep 2. EBioMedicine. 2020. PMID: 32891051 Free PMC article.

2

Test-Retest Performance of a 1-Hour Multiparametric MR Image Acquisition Pipeline With Orthotopic Triple-Negative Breast Cancer Patient-Derived Tumor Xenografts.

Ge X, Quirk JD, Engelbach JA, Bretthorst GL, Li S, Shoghi KI, Garbow JR, Ackerman JJH. Ge X, et al. Among authors: li s. Tomography. 2019 Sep;5(3):320-331. doi: 10.18383/j.tom.2019.00012. Tomography. 2019. PMID: 31572793 Free PMC article.

3

Preclinical PERCIST and 25% of SUV_max Threshold: Precision Imaging of Response to Therapy in Co-clinical ¹⁸F-FDG PET Imaging of Triple-Negative Breast Cancer Patient-Derived Tumor Xenografts.

Savaikar MA, Whitehead T, Roy S, Strong L, Fettig N, Prmeau T, Luo J, Li S, Wahl RL, Shoghi KI. Savaikar MA, et al. Among authors: li s. J Nucl Med. 2020 Jun;61(6):842-849. doi: 10.2967/jnumed.119.234286. Epub 2019 Nov 22. J Nucl Med. 2020. PMID: 31757841 Free PMC article.

4

Co-clinical FDG-PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple-negative breast cancer.

Roy S, Whitehead TD, Li S, Ademuyiwa FO, Wahl RL, Dehdashti F, Shoghi KI. Roy S, et al. Among authors: li s. Eur J Nucl Med Mol Imaging. 2022 Jan;49(2):550-562. doi: 10.1007/s00259-021-05489-8. Epub 2021 Jul 30. Eur J Nucl Med Mol Imaging. 2022. PMID: 34328530 Free PMC article. Clinical Trial.

5

Deep Learning Segmentation of Triple-Negative Breast Cancer (TNBC) Patient Derived Tumor Xenograft (PDX) and Sensitivity of Radiomic Pipeline to Tumor Probability Boundary.

Dutta K, Roy S, Whitehead TD, Luo J, Jha AK, Li S, Quirk JD, Shoghi KI. Dutta K, et al. Among authors: li s. Cancers (Basel). 2021 Jul 28;13(15):3795. doi: 10.3390/cancers13153795. Cancers (Basel). 2021. PMID: 34359696 Free PMC article.

6

Correction to: Co‑clinical FDG‑PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple‑negative breast cancer.

Roy S, Whitehead TD, Li S, Ademuyiwa FO, Wahl RL, Dehdashti F, Shoghi KI. Roy S, et al. Among authors: li s. Eur J Nucl Med Mol Imaging. 2022 Jan;49(2):788. doi: 10.1007/s00259-021-05542-6. Eur J Nucl Med Mol Imaging. 2022. PMID: 34550428 Free PMC article. No abstract available.

7

Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer.

Anurag M, Jaehnig EJ, Krug K, Lei JT, Bergstrom EJ, Kim BJ, Vashist TD, Huynh AMT, Dou Y, Gou X, Huang C, Shi Z, Wen B, Korchina V, Gibbs RA, Muzny DM, Doddapaneni H, Dobrolecki LE, Rodriguez H, Robles AI, Hiltke T, Lewis MT, Nangia JR, Nemati Shafaee M, Li S, Hagemann IS, Hoog J, Lim B, Osborne CK, Mani DR, Gillette MA, Zhang B, Echeverria GV, Miles G, Rimawi MF, Carr SA, Ademuyiwa FO, Satpathy S, Ellis MJ. Anurag M, et al. Among authors: li s. Cancer Discov. 2022 Nov 2;12(11):2586-2605. doi: 10.1158/2159-8290.CD-22-0200. Cancer Discov. 2022. PMID: 36001024 Free PMC article.

8

Animal Models and Their Role in Imaging-Assisted Co-Clinical Trials.

Peehl DM, Badea CT, Chenevert TL, Daldrup-Link HE, Ding L, Dobrolecki LE, Houghton AM, Kinahan PE, Kurhanewicz J, Lewis MT, Li S, Luker GD, Ma CX, Manning HC, Mowery YM, O'Dwyer PJ, Pautler RG, Rosen MA, Roudi R, Ross BD, Shoghi KI, Sriram R, Talpaz M, Wahl RL, Zhou R. Peehl DM, et al. Among authors: li s. Tomography. 2023 Mar 16;9(2):657-680. doi: 10.3390/tomography9020053. Tomography. 2023. PMID: 36961012 Free PMC article. Review.

9

Evaluation of copanlisib in combination with eribulin in triple negative breast cancer patient-derived xenograft models.

Guo Z, Luo J, Mashl RJ, Hoog J, Maiti P, Fettig N, Davies SR, Aft R, Held JM, Govindan R, Ding L, Li S, von Morze C, Wulf GM, Shoghi KI, Ma CX. Guo Z, et al. Among authors: li s. Cancer Res Commun. 2024 May 8. doi: 10.1158/2767-9764.CRC-24-0047. Online ahead of print. Cancer Res Commun. 2024. PMID: 38717161 Free article.

10

Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer.

Rajput S, Khera N, Guo Z, Hoog J, Li S, Ma CX. Rajput S, et al. Among authors: li s. Oncotarget. 2016 Aug 30;7(35):56864-56875. doi: 10.18632/oncotarget.10870. Oncotarget. 2016. PMID: 27486754 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

91,974 results

Search Page